FDA grants orphan drug status to Humira for treatment of hidradenitis suppurativa

AbbVie announced today that the FDA has granted orphan drug designation to Humira for treating moderate-to-severe hidradenitis suppurativa.The supplemental biologic license application by Abbvie seeking the agency’s approval for the use of Humira (adalimumab) in patients with moderate-to-severe hidradenitis suppurativa (HS; Hurley Stage II and Hurley Stage III disease) is being reviewed by the FDA, according to a press release.